KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Gross Profit (2016 - 2026)

Pacira BioSciences has reported Gross Profit over the past 17 years, most recently at $141.0 million for Q1 2026.

  • For Q1 2026, Gross Profit rose 4.71% year-over-year to $141.0 million; the TTM value through Mar 2026 reached $583.0 million, up 6.88%, while the annual FY2025 figure was $576.7 million, 8.69% up from the prior year.
  • Gross Profit for Q1 2026 was $141.0 million at Pacira BioSciences, down from $156.6 million in the prior quarter.
  • Over five years, Gross Profit peaked at $156.6 million in Q4 2025 and troughed at -$541.5 million in Q4 2022.
  • A 5-year average of $91.4 million and a median of $129.7 million in 2024 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: tumbled 550.57% in 2022 and later surged 124.66% in 2023.
  • Year by year, Gross Profit stood at -$541.5 million in 2022, then surged by 124.66% to $133.6 million in 2023, then grew by 10.34% to $147.4 million in 2024, then increased by 6.25% to $156.6 million in 2025, then decreased by 9.97% to $141.0 million in 2026.
  • Business Quant data shows Gross Profit for PCRX at $141.0 million in Q1 2026, $156.6 million in Q4 2025, and $145.2 million in Q3 2025.